Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001140361-25-042006·Innovative Cellular Therapeutics Holdings Ltd
Schedule 13G ownership disclosure
Lyell Immunopharma Inc
Common Stock, par value $0.0001 · CUSIP: 55083R203
Event date: 2025-11-06
- Filing-level shares
- 1,900,000
- Percent of class
- 9.8%
- Innovative Cellular Therapeutics Holdings Ltd
Shares: 1,900,000 · Class: 9.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001140361-25-042006
- Form type
- SCHEDULE 13G
- Filer
- Innovative Cellular Therapeutics Holdings Ltd
- CIK
- CIK 2095697
- Filed
- Nov 13, 2025
- Reporting period
- Nov 06, 2025
- Description
- Schedule 13G beneficial ownership